Bionano Genomics, Inc. Common Stock 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Bio Nano reported strong second quarter 2026 results driven by increased clinical adoption of optical genome mapping (OGM).
- Flow cells sold increased 27% year over year to a record 9,219 units, with consumable revenue up 30% year over year to $4.3 million.
- Software revenue declined 16% year over year to $1.4 million due to timing delays in customer deployments.
- Other revenue, including instruments and services, rose 38% year over year to $2.5 million, led by higher instrument sales.
- International markets represented the majority of total revenue, driven by broadening clinical adoption in Europe.
- The installed base of OGM systems grew 5% year over year to 397 units worldwide.
- Gross margin improved to 53% in Q2 2026, the highest quarterly gross margin to date, with adjusted operating expenses slightly decreased to $8.7 million.
- Bio Nano fully retired its outstanding senior secured convertible debt during the quarter, simplifying its financial profile.
- Total revenue for Q2 2026 was $8.2 million, up 21% compared to Q2 2025 and above guidance.
- Cash, cash equivalents, and available-for-sale securities totaled $10.4 million at quarter-end, with a cash runway extending into at least Q1 2027.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good day, and welcome to the Bionano second quarter 2026 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group.
Please go ahead. Thank you, operator, and good afternoon, everyone.
Welcome to the Bionano second quarter 2026 financial results conference call. On the call today are Dr. Albert Luderer, Chairman and Interim CEO of Bionano, and Mark Adamchak, Bionano's Vice President of Accounting and Principal Accounting Officer. After market close today, Bionano issued a press release announcing its financial results for the second quarter 2026. A copy of the release can be found on the investor relations page of the company's website. Certain statements made during this conference call may be forward-looking statements. Actual results may differ materially from such statements due to several factors and risks, some of which are identified in Bionano's press release and Bionano's report filed with the SEC. These forward-looking statements are based upon information available to Bionano today, August 10, 2026, and the company assumes no obligation to update statements as circumstances change.
During our call, we may reference certain non-GAAP financial measures which we believe provide useful information for investors. Reconciliations of these measures to GAAP can be found on our press release and slide deck. An audio recording and webcast replay of today's conference call will also be available online on the investor relations page of the company website. With that, I will turn the call over to Al.
Well, thank you, Webb, and good afternoon, everyone. I am pleased to be here with you all today to share our second quarter 2026 results. Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers. Our results reflect a vote of confidence from our routine use customer community and the accelerating global adoption of optical genome mapping, or OGM. Importantly, the growth of our consumable sales this quarter was primarily driven by increased clinical adoption. We expect that adoption, together with increased utilization at existing and new clinical sites, to remain the foundation of our growth. Before I get into the quarter, I want to note an important addition to our team. We are pleased to welcome back Dr. Alex Hastie as our Chief Scientific Officer. Alex was one of the original architects of our technology.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring